Loading…
HLA informs risk predictions after haploidentical stem cell transplantation with posttransplantation cyclophosphamide
Hematopoietic cell transplantation from HLA-haploidentical related donors is increasingly used to treat hematologic cancers; however, characteristics of the optimal haploidentical donor have not been established. We studied the role of donor HLA mismatching in graft-versus-host disease (GVHD), disea...
Saved in:
| Published in: | Blood 2022-03, Vol.139 (10), p.1452-1468 |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c447t-b3e2857cd664ccc297bb5ec506a1e890fb0f492d21614eed3d48cfa2d516b1903 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c447t-b3e2857cd664ccc297bb5ec506a1e890fb0f492d21614eed3d48cfa2d516b1903 |
| container_end_page | 1468 |
| container_issue | 10 |
| container_start_page | 1452 |
| container_title | Blood |
| container_volume | 139 |
| creator | Fuchs, Ephraim J. McCurdy, Shannon R. Solomon, Scott R. Wang, Tao Herr, Megan R. Modi, Dipenkumar Grunwald, Michael R. Nishihori, Taiga Kuxhausen, Michelle Fingerson, Stephanie McKallor, Caroline Bashey, Asad Kasamon, Yvette L. Bolon, Yung-Tsi Saad, Ayman McGuirk, Joseph Paczesny, Sophie Gadalla, Shahinaz M. Marsh, Steven G.E. Shaw, Bronwen E. Spellman, Stephen R. Lee, Stephanie J. Petersdorf, Effie W. |
| description | Hematopoietic cell transplantation from HLA-haploidentical related donors is increasingly used to treat hematologic cancers; however, characteristics of the optimal haploidentical donor have not been established. We studied the role of donor HLA mismatching in graft-versus-host disease (GVHD), disease recurrence, and survival after haploidentical donor transplantation with posttransplantation cyclophosphamide (PTCy) for 1434 acute leukemia or myelodysplastic syndrome patients reported to the Center for International Blood and Marrow Transplant Research. The impact of mismatching in the graft-versus-host vector for HLA-A, -B, -C, -DRB1, and -DQB1 alleles, the HLA-B leader, and HLA-DPB1 T-cell epitope (TCE) were studied using multivariable regression methods. Outcome was associated with HLA (mis)matches at individual loci rather than the total number of HLA mismatches. HLA-DRB1 mismatches were associated with lower risk of disease recurrence. HLA-DRB1 mismatching with HLA-DQB1 matching correlated with improved disease-free survival. HLA-B leader matching and HLA-DPB1 TCE-nonpermissive mismatching were each associated with improved overall survival. HLA-C matching lowered chronic GVHD risk, and the level of HLA-C expression correlated with transplant-related mortality. Matching status at the HLA-B leader and HLA-DRB1, -DQB1, and -DPB1 predicted disease-free survival, as did patient and donor cytomegalovirus serostatus, patient age, and comorbidity index. A web-based tool was developed to facilitate selection of the best haploidentical-related donor by calculating disease-free survival based on these characteristics. In conclusion, HLA factors influence the success of haploidentical transplantation with PTCy. HLA-DRB1 and -DPB1 mismatching and HLA-C, -B leader, and -DQB1 matching are favorable. Consideration of HLA factors may help to optimize the selection of haploidentical related donors.
•HLA mismatching is associated with relapse and survival after haploidentical transplantation utilizing posttransplant cyclophosphamide.•HLA should inform the selection of haploidentical donors for transplantation.
[Display omitted] |
| doi_str_mv | 10.1182/blood.2021013443 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8914182</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0006497121018152</els_id><sourcerecordid>2592317341</sourcerecordid><originalsourceid>FETCH-LOGICAL-c447t-b3e2857cd664ccc297bb5ec506a1e890fb0f492d21614eed3d48cfa2d516b1903</originalsourceid><addsrcrecordid>eNp1kT1vFDEQhi0EIpdAT4Vc0mzw2N4vCqQoIgnSSTRJbXntWdbgXS-2L1H-Pb5cCB8SlYt55xnPPIS8AXYK0PH3gw_BnnLGgYGQUjwjG6h5VzHG2XOyYYw1lexbOCLHKX1jDKTg9UtyJGTLZd20G7K72p5Rt4whzolGl77TNaJ1JruwJKrHjJFOevXBWVyyM9rTlHGmBr2nOeolrV4vWe_z9M7lia4h5X8L5t74sE4hrZOeC-kVeTFqn_D143tCbi4-XZ9fVdsvl5_Pz7aVkbLN1SCQd3VrbNNIYwzv22Go0dSs0YBdz8aBjbLnlkMDEtEKKzszam5raAbomTghHw_cdTfMaE1ZIWqv1uhmHe9V0E79XVncpL6GW9X1IMuBC-DdIyCGHztMWc0u7XfXC4ZdUrzuuYBWSChRdoiaGFKKOD6NAab2ttSDLfXbVml5--f3nhp-6SmBD4cAliPdOowqGYeLKYYimqxscP-n_wQoS6np</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2592317341</pqid></control><display><type>article</type><title>HLA informs risk predictions after haploidentical stem cell transplantation with posttransplantation cyclophosphamide</title><source>ScienceDirect</source><creator>Fuchs, Ephraim J. ; McCurdy, Shannon R. ; Solomon, Scott R. ; Wang, Tao ; Herr, Megan R. ; Modi, Dipenkumar ; Grunwald, Michael R. ; Nishihori, Taiga ; Kuxhausen, Michelle ; Fingerson, Stephanie ; McKallor, Caroline ; Bashey, Asad ; Kasamon, Yvette L. ; Bolon, Yung-Tsi ; Saad, Ayman ; McGuirk, Joseph ; Paczesny, Sophie ; Gadalla, Shahinaz M. ; Marsh, Steven G.E. ; Shaw, Bronwen E. ; Spellman, Stephen R. ; Lee, Stephanie J. ; Petersdorf, Effie W.</creator><creatorcontrib>Fuchs, Ephraim J. ; McCurdy, Shannon R. ; Solomon, Scott R. ; Wang, Tao ; Herr, Megan R. ; Modi, Dipenkumar ; Grunwald, Michael R. ; Nishihori, Taiga ; Kuxhausen, Michelle ; Fingerson, Stephanie ; McKallor, Caroline ; Bashey, Asad ; Kasamon, Yvette L. ; Bolon, Yung-Tsi ; Saad, Ayman ; McGuirk, Joseph ; Paczesny, Sophie ; Gadalla, Shahinaz M. ; Marsh, Steven G.E. ; Shaw, Bronwen E. ; Spellman, Stephen R. ; Lee, Stephanie J. ; Petersdorf, Effie W.</creatorcontrib><description>Hematopoietic cell transplantation from HLA-haploidentical related donors is increasingly used to treat hematologic cancers; however, characteristics of the optimal haploidentical donor have not been established. We studied the role of donor HLA mismatching in graft-versus-host disease (GVHD), disease recurrence, and survival after haploidentical donor transplantation with posttransplantation cyclophosphamide (PTCy) for 1434 acute leukemia or myelodysplastic syndrome patients reported to the Center for International Blood and Marrow Transplant Research. The impact of mismatching in the graft-versus-host vector for HLA-A, -B, -C, -DRB1, and -DQB1 alleles, the HLA-B leader, and HLA-DPB1 T-cell epitope (TCE) were studied using multivariable regression methods. Outcome was associated with HLA (mis)matches at individual loci rather than the total number of HLA mismatches. HLA-DRB1 mismatches were associated with lower risk of disease recurrence. HLA-DRB1 mismatching with HLA-DQB1 matching correlated with improved disease-free survival. HLA-B leader matching and HLA-DPB1 TCE-nonpermissive mismatching were each associated with improved overall survival. HLA-C matching lowered chronic GVHD risk, and the level of HLA-C expression correlated with transplant-related mortality. Matching status at the HLA-B leader and HLA-DRB1, -DQB1, and -DPB1 predicted disease-free survival, as did patient and donor cytomegalovirus serostatus, patient age, and comorbidity index. A web-based tool was developed to facilitate selection of the best haploidentical-related donor by calculating disease-free survival based on these characteristics. In conclusion, HLA factors influence the success of haploidentical transplantation with PTCy. HLA-DRB1 and -DPB1 mismatching and HLA-C, -B leader, and -DQB1 matching are favorable. Consideration of HLA factors may help to optimize the selection of haploidentical related donors.
•HLA mismatching is associated with relapse and survival after haploidentical transplantation utilizing posttransplant cyclophosphamide.•HLA should inform the selection of haploidentical donors for transplantation.
[Display omitted]</description><identifier>ISSN: 0006-4971</identifier><identifier>ISSN: 1528-0020</identifier><identifier>EISSN: 1528-0020</identifier><identifier>DOI: 10.1182/blood.2021013443</identifier><identifier>PMID: 34724567</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Cyclophosphamide - therapeutic use ; Graft vs Host Disease - etiology ; Hematopoietic Stem Cell Transplantation - methods ; Histocompatibility Testing ; HLA-B Antigens ; HLA-C Antigens ; HLA-DRB1 Chains ; Humans ; Plenary Paper ; Unrelated Donors</subject><ispartof>Blood, 2022-03, Vol.139 (10), p.1452-1468</ispartof><rights>2022 American Society of Hematology</rights><rights>2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c447t-b3e2857cd664ccc297bb5ec506a1e890fb0f492d21614eed3d48cfa2d516b1903</citedby><cites>FETCH-LOGICAL-c447t-b3e2857cd664ccc297bb5ec506a1e890fb0f492d21614eed3d48cfa2d516b1903</cites><orcidid>0000-0002-6454-3683 ; 0000-0002-2621-7924 ; 0000-0002-3255-8143 ; 0000-0001-6525-8844 ; 0000-0001-5768-9396 ; 0000-0003-0003-0130 ; 0000-0003-2161-8259 ; 0000-0002-2596-6843 ; 0000-0001-5571-2775 ; 0000-0002-0539-4796</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0006497121018152$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,315,786,790,891,3568,27957,27958,45815</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34724567$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Fuchs, Ephraim J.</creatorcontrib><creatorcontrib>McCurdy, Shannon R.</creatorcontrib><creatorcontrib>Solomon, Scott R.</creatorcontrib><creatorcontrib>Wang, Tao</creatorcontrib><creatorcontrib>Herr, Megan R.</creatorcontrib><creatorcontrib>Modi, Dipenkumar</creatorcontrib><creatorcontrib>Grunwald, Michael R.</creatorcontrib><creatorcontrib>Nishihori, Taiga</creatorcontrib><creatorcontrib>Kuxhausen, Michelle</creatorcontrib><creatorcontrib>Fingerson, Stephanie</creatorcontrib><creatorcontrib>McKallor, Caroline</creatorcontrib><creatorcontrib>Bashey, Asad</creatorcontrib><creatorcontrib>Kasamon, Yvette L.</creatorcontrib><creatorcontrib>Bolon, Yung-Tsi</creatorcontrib><creatorcontrib>Saad, Ayman</creatorcontrib><creatorcontrib>McGuirk, Joseph</creatorcontrib><creatorcontrib>Paczesny, Sophie</creatorcontrib><creatorcontrib>Gadalla, Shahinaz M.</creatorcontrib><creatorcontrib>Marsh, Steven G.E.</creatorcontrib><creatorcontrib>Shaw, Bronwen E.</creatorcontrib><creatorcontrib>Spellman, Stephen R.</creatorcontrib><creatorcontrib>Lee, Stephanie J.</creatorcontrib><creatorcontrib>Petersdorf, Effie W.</creatorcontrib><title>HLA informs risk predictions after haploidentical stem cell transplantation with posttransplantation cyclophosphamide</title><title>Blood</title><addtitle>Blood</addtitle><description>Hematopoietic cell transplantation from HLA-haploidentical related donors is increasingly used to treat hematologic cancers; however, characteristics of the optimal haploidentical donor have not been established. We studied the role of donor HLA mismatching in graft-versus-host disease (GVHD), disease recurrence, and survival after haploidentical donor transplantation with posttransplantation cyclophosphamide (PTCy) for 1434 acute leukemia or myelodysplastic syndrome patients reported to the Center for International Blood and Marrow Transplant Research. The impact of mismatching in the graft-versus-host vector for HLA-A, -B, -C, -DRB1, and -DQB1 alleles, the HLA-B leader, and HLA-DPB1 T-cell epitope (TCE) were studied using multivariable regression methods. Outcome was associated with HLA (mis)matches at individual loci rather than the total number of HLA mismatches. HLA-DRB1 mismatches were associated with lower risk of disease recurrence. HLA-DRB1 mismatching with HLA-DQB1 matching correlated with improved disease-free survival. HLA-B leader matching and HLA-DPB1 TCE-nonpermissive mismatching were each associated with improved overall survival. HLA-C matching lowered chronic GVHD risk, and the level of HLA-C expression correlated with transplant-related mortality. Matching status at the HLA-B leader and HLA-DRB1, -DQB1, and -DPB1 predicted disease-free survival, as did patient and donor cytomegalovirus serostatus, patient age, and comorbidity index. A web-based tool was developed to facilitate selection of the best haploidentical-related donor by calculating disease-free survival based on these characteristics. In conclusion, HLA factors influence the success of haploidentical transplantation with PTCy. HLA-DRB1 and -DPB1 mismatching and HLA-C, -B leader, and -DQB1 matching are favorable. Consideration of HLA factors may help to optimize the selection of haploidentical related donors.
•HLA mismatching is associated with relapse and survival after haploidentical transplantation utilizing posttransplant cyclophosphamide.•HLA should inform the selection of haploidentical donors for transplantation.
[Display omitted]</description><subject>Cyclophosphamide - therapeutic use</subject><subject>Graft vs Host Disease - etiology</subject><subject>Hematopoietic Stem Cell Transplantation - methods</subject><subject>Histocompatibility Testing</subject><subject>HLA-B Antigens</subject><subject>HLA-C Antigens</subject><subject>HLA-DRB1 Chains</subject><subject>Humans</subject><subject>Plenary Paper</subject><subject>Unrelated Donors</subject><issn>0006-4971</issn><issn>1528-0020</issn><issn>1528-0020</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNp1kT1vFDEQhi0EIpdAT4Vc0mzw2N4vCqQoIgnSSTRJbXntWdbgXS-2L1H-Pb5cCB8SlYt55xnPPIS8AXYK0PH3gw_BnnLGgYGQUjwjG6h5VzHG2XOyYYw1lexbOCLHKX1jDKTg9UtyJGTLZd20G7K72p5Rt4whzolGl77TNaJ1JruwJKrHjJFOevXBWVyyM9rTlHGmBr2nOeolrV4vWe_z9M7lia4h5X8L5t74sE4hrZOeC-kVeTFqn_D143tCbi4-XZ9fVdsvl5_Pz7aVkbLN1SCQd3VrbNNIYwzv22Go0dSs0YBdz8aBjbLnlkMDEtEKKzszam5raAbomTghHw_cdTfMaE1ZIWqv1uhmHe9V0E79XVncpL6GW9X1IMuBC-DdIyCGHztMWc0u7XfXC4ZdUrzuuYBWSChRdoiaGFKKOD6NAab2ttSDLfXbVml5--f3nhp-6SmBD4cAliPdOowqGYeLKYYimqxscP-n_wQoS6np</recordid><startdate>20220310</startdate><enddate>20220310</enddate><creator>Fuchs, Ephraim J.</creator><creator>McCurdy, Shannon R.</creator><creator>Solomon, Scott R.</creator><creator>Wang, Tao</creator><creator>Herr, Megan R.</creator><creator>Modi, Dipenkumar</creator><creator>Grunwald, Michael R.</creator><creator>Nishihori, Taiga</creator><creator>Kuxhausen, Michelle</creator><creator>Fingerson, Stephanie</creator><creator>McKallor, Caroline</creator><creator>Bashey, Asad</creator><creator>Kasamon, Yvette L.</creator><creator>Bolon, Yung-Tsi</creator><creator>Saad, Ayman</creator><creator>McGuirk, Joseph</creator><creator>Paczesny, Sophie</creator><creator>Gadalla, Shahinaz M.</creator><creator>Marsh, Steven G.E.</creator><creator>Shaw, Bronwen E.</creator><creator>Spellman, Stephen R.</creator><creator>Lee, Stephanie J.</creator><creator>Petersdorf, Effie W.</creator><general>Elsevier Inc</general><general>American Society of Hematology</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-6454-3683</orcidid><orcidid>https://orcid.org/0000-0002-2621-7924</orcidid><orcidid>https://orcid.org/0000-0002-3255-8143</orcidid><orcidid>https://orcid.org/0000-0001-6525-8844</orcidid><orcidid>https://orcid.org/0000-0001-5768-9396</orcidid><orcidid>https://orcid.org/0000-0003-0003-0130</orcidid><orcidid>https://orcid.org/0000-0003-2161-8259</orcidid><orcidid>https://orcid.org/0000-0002-2596-6843</orcidid><orcidid>https://orcid.org/0000-0001-5571-2775</orcidid><orcidid>https://orcid.org/0000-0002-0539-4796</orcidid></search><sort><creationdate>20220310</creationdate><title>HLA informs risk predictions after haploidentical stem cell transplantation with posttransplantation cyclophosphamide</title><author>Fuchs, Ephraim J. ; McCurdy, Shannon R. ; Solomon, Scott R. ; Wang, Tao ; Herr, Megan R. ; Modi, Dipenkumar ; Grunwald, Michael R. ; Nishihori, Taiga ; Kuxhausen, Michelle ; Fingerson, Stephanie ; McKallor, Caroline ; Bashey, Asad ; Kasamon, Yvette L. ; Bolon, Yung-Tsi ; Saad, Ayman ; McGuirk, Joseph ; Paczesny, Sophie ; Gadalla, Shahinaz M. ; Marsh, Steven G.E. ; Shaw, Bronwen E. ; Spellman, Stephen R. ; Lee, Stephanie J. ; Petersdorf, Effie W.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c447t-b3e2857cd664ccc297bb5ec506a1e890fb0f492d21614eed3d48cfa2d516b1903</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Cyclophosphamide - therapeutic use</topic><topic>Graft vs Host Disease - etiology</topic><topic>Hematopoietic Stem Cell Transplantation - methods</topic><topic>Histocompatibility Testing</topic><topic>HLA-B Antigens</topic><topic>HLA-C Antigens</topic><topic>HLA-DRB1 Chains</topic><topic>Humans</topic><topic>Plenary Paper</topic><topic>Unrelated Donors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Fuchs, Ephraim J.</creatorcontrib><creatorcontrib>McCurdy, Shannon R.</creatorcontrib><creatorcontrib>Solomon, Scott R.</creatorcontrib><creatorcontrib>Wang, Tao</creatorcontrib><creatorcontrib>Herr, Megan R.</creatorcontrib><creatorcontrib>Modi, Dipenkumar</creatorcontrib><creatorcontrib>Grunwald, Michael R.</creatorcontrib><creatorcontrib>Nishihori, Taiga</creatorcontrib><creatorcontrib>Kuxhausen, Michelle</creatorcontrib><creatorcontrib>Fingerson, Stephanie</creatorcontrib><creatorcontrib>McKallor, Caroline</creatorcontrib><creatorcontrib>Bashey, Asad</creatorcontrib><creatorcontrib>Kasamon, Yvette L.</creatorcontrib><creatorcontrib>Bolon, Yung-Tsi</creatorcontrib><creatorcontrib>Saad, Ayman</creatorcontrib><creatorcontrib>McGuirk, Joseph</creatorcontrib><creatorcontrib>Paczesny, Sophie</creatorcontrib><creatorcontrib>Gadalla, Shahinaz M.</creatorcontrib><creatorcontrib>Marsh, Steven G.E.</creatorcontrib><creatorcontrib>Shaw, Bronwen E.</creatorcontrib><creatorcontrib>Spellman, Stephen R.</creatorcontrib><creatorcontrib>Lee, Stephanie J.</creatorcontrib><creatorcontrib>Petersdorf, Effie W.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Blood</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Fuchs, Ephraim J.</au><au>McCurdy, Shannon R.</au><au>Solomon, Scott R.</au><au>Wang, Tao</au><au>Herr, Megan R.</au><au>Modi, Dipenkumar</au><au>Grunwald, Michael R.</au><au>Nishihori, Taiga</au><au>Kuxhausen, Michelle</au><au>Fingerson, Stephanie</au><au>McKallor, Caroline</au><au>Bashey, Asad</au><au>Kasamon, Yvette L.</au><au>Bolon, Yung-Tsi</au><au>Saad, Ayman</au><au>McGuirk, Joseph</au><au>Paczesny, Sophie</au><au>Gadalla, Shahinaz M.</au><au>Marsh, Steven G.E.</au><au>Shaw, Bronwen E.</au><au>Spellman, Stephen R.</au><au>Lee, Stephanie J.</au><au>Petersdorf, Effie W.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>HLA informs risk predictions after haploidentical stem cell transplantation with posttransplantation cyclophosphamide</atitle><jtitle>Blood</jtitle><addtitle>Blood</addtitle><date>2022-03-10</date><risdate>2022</risdate><volume>139</volume><issue>10</issue><spage>1452</spage><epage>1468</epage><pages>1452-1468</pages><issn>0006-4971</issn><issn>1528-0020</issn><eissn>1528-0020</eissn><notes>ObjectType-Article-1</notes><notes>SourceType-Scholarly Journals-1</notes><notes>ObjectType-Feature-2</notes><notes>content type line 23</notes><notes>E.J.F. and S.R.M. contributed equally to this study.</notes><abstract>Hematopoietic cell transplantation from HLA-haploidentical related donors is increasingly used to treat hematologic cancers; however, characteristics of the optimal haploidentical donor have not been established. We studied the role of donor HLA mismatching in graft-versus-host disease (GVHD), disease recurrence, and survival after haploidentical donor transplantation with posttransplantation cyclophosphamide (PTCy) for 1434 acute leukemia or myelodysplastic syndrome patients reported to the Center for International Blood and Marrow Transplant Research. The impact of mismatching in the graft-versus-host vector for HLA-A, -B, -C, -DRB1, and -DQB1 alleles, the HLA-B leader, and HLA-DPB1 T-cell epitope (TCE) were studied using multivariable regression methods. Outcome was associated with HLA (mis)matches at individual loci rather than the total number of HLA mismatches. HLA-DRB1 mismatches were associated with lower risk of disease recurrence. HLA-DRB1 mismatching with HLA-DQB1 matching correlated with improved disease-free survival. HLA-B leader matching and HLA-DPB1 TCE-nonpermissive mismatching were each associated with improved overall survival. HLA-C matching lowered chronic GVHD risk, and the level of HLA-C expression correlated with transplant-related mortality. Matching status at the HLA-B leader and HLA-DRB1, -DQB1, and -DPB1 predicted disease-free survival, as did patient and donor cytomegalovirus serostatus, patient age, and comorbidity index. A web-based tool was developed to facilitate selection of the best haploidentical-related donor by calculating disease-free survival based on these characteristics. In conclusion, HLA factors influence the success of haploidentical transplantation with PTCy. HLA-DRB1 and -DPB1 mismatching and HLA-C, -B leader, and -DQB1 matching are favorable. Consideration of HLA factors may help to optimize the selection of haploidentical related donors.
•HLA mismatching is associated with relapse and survival after haploidentical transplantation utilizing posttransplant cyclophosphamide.•HLA should inform the selection of haploidentical donors for transplantation.
[Display omitted]</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>34724567</pmid><doi>10.1182/blood.2021013443</doi><tpages>17</tpages><orcidid>https://orcid.org/0000-0002-6454-3683</orcidid><orcidid>https://orcid.org/0000-0002-2621-7924</orcidid><orcidid>https://orcid.org/0000-0002-3255-8143</orcidid><orcidid>https://orcid.org/0000-0001-6525-8844</orcidid><orcidid>https://orcid.org/0000-0001-5768-9396</orcidid><orcidid>https://orcid.org/0000-0003-0003-0130</orcidid><orcidid>https://orcid.org/0000-0003-2161-8259</orcidid><orcidid>https://orcid.org/0000-0002-2596-6843</orcidid><orcidid>https://orcid.org/0000-0001-5571-2775</orcidid><orcidid>https://orcid.org/0000-0002-0539-4796</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0006-4971 |
| ispartof | Blood, 2022-03, Vol.139 (10), p.1452-1468 |
| issn | 0006-4971 1528-0020 1528-0020 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8914182 |
| source | ScienceDirect |
| subjects | Cyclophosphamide - therapeutic use Graft vs Host Disease - etiology Hematopoietic Stem Cell Transplantation - methods Histocompatibility Testing HLA-B Antigens HLA-C Antigens HLA-DRB1 Chains Humans Plenary Paper Unrelated Donors |
| title | HLA informs risk predictions after haploidentical stem cell transplantation with posttransplantation cyclophosphamide |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-09-21T18%3A04%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=HLA%20informs%20risk%20predictions%20after%20haploidentical%20stem%20cell%20transplantation%20with%20posttransplantation%20cyclophosphamide&rft.jtitle=Blood&rft.au=Fuchs,%20Ephraim%20J.&rft.date=2022-03-10&rft.volume=139&rft.issue=10&rft.spage=1452&rft.epage=1468&rft.pages=1452-1468&rft.issn=0006-4971&rft.eissn=1528-0020&rft_id=info:doi/10.1182/blood.2021013443&rft_dat=%3Cproquest_pubme%3E2592317341%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c447t-b3e2857cd664ccc297bb5ec506a1e890fb0f492d21614eed3d48cfa2d516b1903%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2592317341&rft_id=info:pmid/34724567&rfr_iscdi=true |